Merck/Ridgeback’s Lagevrio Could Get Another Chance As Others Face Limitations
New Analysis Shows No COVID-19 At Days 3 Or 5
New data for molnupiravir could mean new commercial life for Merck and Ridgeback’s oral COVID-19 therapy, which had fallen behind due to the outstanding efficacy for Pfizer’s Paxlovid.
